文献速递关节外科

围手术期使用非生物改善病情抗风湿药对类风湿关节炎患者全膝关节置换术围手术期失血及并发症的影响

The Impact of Perioperative Use of Nonbiologic Disease-Modifying Anti-rheumatic Drugs on Perioperative Blood Loss and Complications in Patients Who Have Rheumatoid Arthritis Undergoing Total Knee Arthroplasty.
PubMed 文献 · J Arthroplasty · 2023-02-09

该回顾性研究纳入2017至2021年因膝类风湿关节炎行全膝关节置换术的患者,比较使用(n=73)与未使用(n=84)非生物改善病情抗风湿药者的围手术期失血、并发症及异体输血,并与骨关节炎患者按1:1或1:2匹配。结果显示两组类风湿关节炎患者在上述结局上无统计学差异,但类风湿关节炎患者的失血量显著大于骨关节炎患者。

要点

  • 使用与未使用改善病情抗风湿药的类风湿关节炎患者围手术期失血无统计学差异。
  • 两组并发症及异体输血无统计学差异。
  • 类风湿关节炎患者总失血、术中失血及隐性失血均显著大于骨关节炎患者。

核心结论

  • 类风湿关节炎患者围手术期失血大于骨关节炎患者,但使用与未使用改善病情抗风湿药的类风湿关节炎患者之间围手术期失血、并发症及异体输血无统计学差异。

研究设计与样本

  • 回顾性纳入2017至2021年在本院因膝类风湿关节炎行全膝关节置换术并使用改善病情抗风湿药(n=73)或未使用(n=84)的患者,每例类风湿关节炎患者按1:1或1:2与骨关节炎患者匹配。

主要发现

  • 使用改善病情抗风湿药的类风湿关节炎患者与未使用者相比,平均总失血804 mL vs 728 mL(P=0.114)、平均术中失血113 mL vs 101 mL(P=0.488)、隐性失血705 mL vs 640 mL(P=0.340),均无统计学差异。
  • 使用改善病情抗风湿药的类风湿关节炎患者与骨关节炎患者相比,平均总失血804 mL vs 654 mL(P=0.001)、术中失血113 mL vs 75 mL(P=0.002)、隐性失血705 mL vs 560 mL(P=0.016),类风湿关节炎患者失血更多。
  • 并发症及异体输血在类风湿关节炎使用与未使用改善病情抗风湿药患者之间无统计学差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of disease-modifying antirheumatic drugs (DMARDs) before total knee arthroplasty (TKA) was associated with increased risk of postoperative periprosthetic joint and wound infections as well as worse platelet function in patients who have knee rheumatoid arthritis (RA). This study investigated the effects of DMARDS on perioperative blood loss, complications, and blood transfusion in patients undergoing TKA for knee RA. METHODS: We retrospectively enrolled patients undergoing TKA for knee RA at our hospital between 2017 and 2021 who received DMARDs (n = 73) or not (n = 84). Every RA patient was matched with patients who had osteoarthritis (OA) in a ratio of 1:1 or 1:2. Primary outcomes were intraoperative and perioperative blood losses, while secondary outcomes were complications and allogeneic transfusions. RESULTS: The mean total (804 versus 728 mL (mL), P = .114), mean intraoperative (113 versus 101 mL, P = .488), or hidden blood losses (705 versus 640 mL, P = .340) did not differ statistically between RA patients who received DMARDs versus those who did not. RA patients who received DMARDs showed significantly greater mean total (804 versus 654 mL, P = .001), intraoperative (113 versus 75 mL, P = .002), and hidden blood losses (705 versus 560 mL, P = .016) than OA patients. No statistical differences were found in complications or allogeneic transfusions. CONCLUSION: Although RA patients experienced greater perioperative blood loss than OA patients, there was no statistical difference in perioperative blood loss, complications, or allogeneic transfusions between RA patients who received DMARDs and those who did not.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Jiang W, Jiang X, Xu H, et al. The Impact of Perioperative Use of Nonbiologic Disease-Modifying Anti-rheumatic Drugs on Perioperative Blood Loss and Complications in Patients Who Have Rheumatoid Arthritis Undergoing Total Knee Arthroplasty. J Arthroplasty. 2023. PMID: 36764400. doi:10.1016/j.arth.2023.01.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。